Rare, Cell, and Gene Therapy

Flexible solutions for an evolving landscape

Fractional Leadership and Executive Search Solutions in Rare, Cell, and Gene Therapy

Accelerating Innovation Through Strategic Leadership

In today’s rapidly evolving therapeutic landscape, companies developing cell, gene, and rare disease therapies face unique challenges in building and scaling their executive teams. Success depends on having the right leadership in place—whether it’s a Chief Medical Officer, a VP of Regulatory Affairs or seasoned experts in Commercial and Clinical Operations.

With over 7,000 rare diseases affecting 400 million people globally, and breakthrough cell and gene therapies offering new hope, strategic leadership is more critical than ever before. The industry’s unprecedented growth—with first-time launches projected to outnumber established company launches by 2026—demands experienced executives who can navigate complex regulatory pathways and drive successful commercialization.

Compass understands the distinct needs of organizations developing treatments for rare diseases and innovative cell and gene therapies. Our deep industry knowledge and extensive network of senior-level talent enable us to provide strategic executive search solutions that align with your development timeline and commercial goals. From fractional leadership roles to operational support, we connect you with executives who can drive your therapeutic innovations forward.  

Why Cell, Gene & Rare Disease Companies Choose Compass

  • Specialized focus on rare disease, cell therapy, and gene therapy staffing
  • Track record of successful placements in emerging biotech companies
  • Understanding of market nuances and regulatory challenges
  • Flexible staffing solutions, including fractional leadership, designed for rapid-growth environments and lean organizational structures
  • Experience with pre-commercial stage companies
  • Ability to scale support as your company evolves
  • Rapid deployment of qualified experts
  • Strategic hiring aligned with development timelines
  • Access to pre-vetted candidates with relevant experience
  • Ability to build entire functional teams quickly

Recent Placement Successes

We’ve earned our stripes working with some of the biggest names in the industry. Our track record is a testament to our ability to deliver exceptional results and exceed expectations.

How Compass’ Senior Director of Quality Assurance Positioned a Gene Therapy Developer for IND-Enabling Success

Drug development accelerators are transforming how treatments move from concept to clinic, particularly in the rare disease and gene therapy space. These organizations face unique challenges as they work to compress traditional development timelines while maintaining rigorous quality standards.

How Compass Empowered a Rare Disease and Gene Therapy Pioneer in Their IND-Enabling Studies

Therapeutics companies at the forefront of rare disease research often find themselves navigating a complex maze of scientific innovation, regulatory requirements, and resource constraints. These organizations frequently face the dual challenge of advancing cutting-edge therapies while operating within the limits of specialized talent and funding availability.

Compass Places Vice President, Clinical Development at Clinical-Stage Biotech

 Compass Consulting Group, a premier staffing and recruiting firm specializing in gene therapy, cell therapy, and rare disease sectors of the life sciences industry, is pleased to announce the successful placement of a Vice President of Clinical Development at a clinical-stage biotechnology company.

Our Life Science Specialties

We deliver talent and strategic solutions across every phase of the life sciences asset development—from R&D to Commercialization.

Partner with Compass

Let’s discuss how we can help you build the team you need to bring your revolutionary therapies to market. Contact us for a consultation with our cell and gene therapy staffing experts.

Cell, Gene & Rare Disease Therapy

  • This field is for validation purposes and should be left unchanged.